|
|
|||
|
|||
|
|
|||
|
class action suits for hytrin |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
class action suits for hytrin Manufacturer: Abbott
Terazosin hydrochloride is a white, crystalline substance, freely soluble inwater and isotonic saline and has a molecular weight of 459.93 class action suits for hytrin. HYTRIN capsules(terazosin hydrochloride capsules) for oral ingestion are supplied in four dosagestrengths containing terazosin hydrochloride equivalent to 1 mg, 2 mg, 5 mg,or 10 mg of terazosin class action suits for hytrin. Inactive Ingredients: 2 mg capsules: D&C yellow No class action suits for hytrin. 10, gelatin, glycerin, methylparaben, mineraloil, polyethylene glycol, povidone, propylparaben, titanium dioxide, and vanillin class action suits for hytrin. 5 mg capsules: D&C red No class action suits for hytrin. 28, FD&C red No class action suits for hytrin. 40, gelatin, glycerin,methylparaben, mineral oil, polyethylene glycol, povidone, propylparaben, titaniumdioxide, and vanillin class action suits for hytrin. 10 mg capsules: FD&C blue No class action suits for hytrin. 1, gelatin, glycerin, methylparaben, mineraloil, polyethylene glycol, povidone, propylparaben, titanium dioxide, and vanillin class action suits for hytrin.
Terazosin has been studied in 1222 men with symptomatic BPH class action suits for hytrin. In three placebo-controlledstudies, symptom evaluation and uroflowmetric measurements were performed approximately24 hours following dosing class action suits for hytrin. Symptoms were quantified using the Boyarsky Index class action suits for hytrin. The questionnaire evaluated both obstructive (hesitancy, intermittency, terminaldribbling, impairment of size and force of stream, sensation of incomplete bladderemptying) and irritative (nocturia, daytime frequency, urgency, dysuria) symptomsby rating each of the 9 symptoms from 0-3, for a total score of 27 points class action suits for hytrin. Resultsfrom these studies indicated that terazosin statistically significantly improvedsymptoms and peak urine flow rates over placebo as follows: N Symptom Score
Analysis of the effect of terazosin on individual urinary symptoms demonstratedthat compared to placebo, terazosin significantly improved the symptoms of hesitancy,intermittency, impairment in size and force of urinary stream, sensation ofincomplete emptying, terminal dribbling, daytime frequency and nocturia class action suits for hytrin. Global assessments of overall urinary function and symptoms were also performedby investigators who were blinded to patient treatment assignment class action suits for hytrin. In studies1 and 3, patients treated with terazosin had a significantly (p </= 0.001)greater overall improvement compared to placebo treated patients class action suits for hytrin. In a short term study (Study 1), patients were randomized to either 2, 5 or10 mg of terazosin or placebo class action suits for hytrin. Patients randomized to the 10 mg group achieveda statistically significant response in both symptoms and peak flow rate comparedto placebo (Figure 1) class action suits for hytrin. + for baseline values see above table * p </= 0.05, compared to placebo group In a long-term, open-label, non-placebo controlled clinical trial, 181 menwere followed for 2 years and 58 of these men were followed for 30 months class action suits for hytrin. Theeffect of terazosin on urinary symptom scores and peak flow rates was maintainedthroughout the study duration (Figures 2 and 3): In this long-term trial, both symptom scores and peak urinary flow rates showedstatistically significant improvement suggesting a relaxation of smooth musclecells class action suits for hytrin. Although blockade of alpha-1 adrenoceptors also lowers blood pressure in hypertensivepatients with increased peripheral vascular resistance, terazosin treatmentof normotensive men with BPH did not result in a clinically significant bloodpressure lowering effect: Mean Changes in Blood Pressure from
Patients in clinical trials of terazosin were administered once daily (thegreat majority) and twice daily regimens with total doses usually in the rangeof 5-20 mg/day, and had mild (about 77%, diastolic pressure 95-105 mmHg) ormoderate (23%, diastolic pressure 105-115 mmHg) hypertension class action suits for hytrin. Because terazosin,like all alpha antagonists, can cause unusually large falls in blood pressureafter the first dose or first few doses, the initial dose was 1 mg in virtuallyall trials, with subsequent titration to a specified fixed dose or titrationto some specified blood pressure end point (usually a supine diastolic pressureof 90 mmHg) class action suits for hytrin. Blood pressure responses were measured at the end of the dosing interval (usually24 hours) and effects were shown to persist throughout the interval, with theusual supine responses 5-10 mmHg systolic and 3.5-8 mmHg diastolic greater thanplacebo class action suits for hytrin. The responses in the standing position tended to be somewhat larger,by 1-3 mmHg, although this was not true in all studies class action suits for hytrin. The magnitude of theblood pressure responses was similar to prazosin and less than hydrochlorothiazide(in a single study of hypertensive patients) class action suits for hytrin. In measurements 24 hours afterdosing, heart rate was unchanged class action suits for hytrin. Limited measurements of peak response (2-3 hours after dosing) during chronicterazosin administration indicate that it is greater than about twice the trough(24 hour) response, suggesting some attenuation of response at 24 hours, presumablydue to a fall in blood terazosin concentrations at the end of the dose interval class action suits for hytrin. This explanation is not established with certainty, however, and is not consistentwith the similarity of blood pressure response to once daily and twice dailydosing and with the absence of an observed dose-response relationship over arange of 5-20 mg, i.e., if blood concentrations had fallen to the point of providingless than full effect at 24 hours, a shorter dosing interval or larger doseshould have led to increased response class action suits for hytrin. Further dose response and dose duration studies are being carried out class action suits for hytrin. Bloodpressure should be measured at the end of the dose interval; if response isnot satisfactory, patients may be tried on a larger dose or twice daily dosingregimen class action suits for hytrin. The latter should also be considered if possibly blood pressure-relatedside effects, such as dizziness, palpitations, or orthostatic complaints, areseen within a few hours after dosing class action suits for hytrin. The greater blood pressure effect associated with peak plasma concentrations(first few hours after dosing) appears somewhat more position-dependent (greaterin the erect position) than the effect of terazosin at 24 hours and in the erectposition there is also a 6-10 beat per minute increase in heart rate in thefirst few hours after dosing class action suits for hytrin. During the first 3 hours after dosing 12.5% ofpatients had a systolic pressure fall of 30 mmHg or more from supine to standing,or standing systolic pressure below 90 mmHg with a fall of at least 20 mmHg,compared to 4% of a placebo group class action suits for hytrin. There was a tendency for patients to gain weight during terazosin therapy class action suits for hytrin. In placebo-controlled monotherapy trials, male and female patients receivingterazosin gained a mean of 1.7 and 2.2 pounds respectively, compared to lossesof 0.2 and 1.2 pounds respectively in the placebo group class action suits for hytrin. Both differences werestatistically significant class action suits for hytrin. During controlled clinical trials, patients receiving terazosin monotherapyhad a small but statistically significant decrease (a 3% fall) compared to placeboin total cholesterol and the combined low-density and very-low-density lipoproteinfractions class action suits for hytrin. No significant changes were observed in high-density lipoproteinfraction and triglycerides compared to placebo class action suits for hytrin. Analysis of clinical laboratory data following administration of terazosinsuggested the possibility of hemodilution based on decreases in hematocrit,hemoglobin, white blood cells, total protein and albumin class action suits for hytrin. Decreases in hematocritand total protein have been observed with alpha-blockade and are attributedto hemodilution class action suits for hytrin. |
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| cclass action suits for hytrin cllass action suits for hytrin claass action suits for hytrin classs action suits for hytrin classs action suits for hytrin class action suits for hytrin class aaction suits for hytrin class acction suits for hytrin class acttion suits for hytrin class actiion suits for hytrin class actioon suits for hytrin class actionn suits for hytrin class action suits for hytrin class action ssuits for hytrin class action suuits for hytrin class action suiits for hytrin class action suitts for hytrin class action suitss for hytrin class action suits for hytrin class action suits ffor hytrin class action suits foor hytrin class action suits forr hytrin class action suits for hytrin class action suits for hhytrin class action suits for hyytrin class action suits for hyttrin class action suits for hytrrin class action suits for hytriin class action suits for hytrinn lass action suits for hytrin cass action suits for hytrin clss action suits for hytrin clas action suits for hytrin clas action suits for hytrin classaction suits for hytrin class ction suits for hytrin class ation suits for hytrin class acion suits for hytrin class acton suits for hytrin class actin suits for hytrin class actio suits for hytrin class actionsuits for hytrin class action uits for hytrin class action sits for hytrin class action suts for hytrin class action suis for hytrin class action suit for hytrin class action suitsfor hytrin class action suits or hytrin class action suits fr hytrin class action suits fo hytrin class action suits forhytrin class action suits for ytrin class action suits for htrin class action suits for hyrin class action suits for hytin class action suits for hytrn class action suits for hytri c lass action suits for hytrin cl ass action suits for hytrin cla ss action suits for hytrin clas s action suits for hytrin class action suits for hytrin class action suits for hytrin class a ction suits for hytrin class ac tion suits for hytrin class act ion suits for hytrin class acti on suits for hytrin class actio n suits for hytrin class action suits for hytrin class action suits for hytrin class action s uits for hytrin class action su its for hytrin class action sui ts for hytrin class action suit s for hytrin class action suits for hytrin class action suits for hytrin class action suits f or hytrin class action suits fo r hytrin class action suits for hytrin class action suits for hytrin class action suits for h ytrin class action suits for hy trin class action suits for hyt rin class action suits for hytr in class action suits for hytri n class action suits for hytrin lcass action suits for hytrin calss action suits for hytrin clsas action suits for hytrin class action suits for hytrin clas saction suits for hytrin classa ction suits for hytrin class cation suits for hytrin class atcion suits for hytrin class aciton suits for hytrin class actoin suits for hytrin class actino suits for hytrin class actio nsuits for hytrin class actions uits for hytrin class action usits for hytrin class action siuts for hytrin class action sutis for hytrin class action suist for hytrin class action suit sfor hytrin class action suitsf or hytrin class action suits ofr hytrin class action suits fro hytrin class action suits fo rhytrin class action suits forh ytrin class action suits for yhtrin class action suits for htyrin class action suits for hyrtin class action suits for hytirn class action suits for hytrni aclass action suits for hytrin theclass action suits for hytrin class action suits for hytrin | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
